KTRA Stock Price, Kintara Therapeutics, . Quote, Chart

Market Summary

USD0.150.00

Market Closed

0.00%

KTRA Stock Price

View Fullscreen

KTRA RSI Chart

KTRA Valuation

Market Cap

5.9B

Price/Earnings (Trailing)

-553.26

Price/Sales (Trailing)

1.6M

Price/Free Cashflow

-865.07

KTRA Price/Sales (Trailing)

KTRA Profitability

Return on Equity

6.5K%

Return on Assets

-561.49%

Free Cashflow Yield

-0.12%

KTRA Fundamentals

KTRA Revenue

Revenue (TTM)

2.5K

KTRA Earnings

Earnings (TTM)

-10.6M

Earnings Growth (Yr)

70.38%

Earnings Growth (Qtr)

65.46%

Breaking Down KTRA Revenue

Last 7 days

-6.2%

Last 30 days

15.4%

Last 90 days

36.4%

Trailing 12 Months

-95.3%

How does KTRA drawdown profile look like?

KTRA Financial Health

Current Ratio

0.63

KTRA Investor Care

Shares Dilution (1Y)

2330096.53%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2014	0	0	0	0
2013	0	13.8K	8.9K	5.7K
2012	11.4K	11.6K	12.3K	13.1K
2011	0	10.7K	10.9K	11.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kintara Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 01, 2023	hoffman robert e.	acquired	-	-	59,800	president, ceo, and cfo
Jan 05, 2023	brown dennis m	acquired	-	-	363	chief scientific officer
Aug 01, 2022	hoffman robert e.	acquired	-	-	400,145	president and ceo
Aug 01, 2022	brown dennis m	acquired	-	-	240,087	chief scientific officer
Aug 01, 2022	praill anthony scott	acquired	-	-	240,087	chief financial officer
Feb 15, 2022	hoffman robert e.	bought	25,795	0.469	55,000	president and ceo
Dec 08, 2021	praill anthony scott	bought	19,429	0.677	28,700	chief financial officer
Dec 07, 2021	zarrabian saiid	bought	24,298	0.6376	38,109	head of strategic partnerships
Dec 06, 2021	zarrabian saiid	bought	7,018	0.5902	11,891	head of strategic partnerships
Nov 22, 2021	johnson laura l.	bought	2,226	0.7423	3,000	-

Which funds bought or sold KTRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 16, 2024	Stratos Wealth Partners, LTD.	sold off	-100	-3,392	-	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	sold off	-100	-7.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-48,206	2,112	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	94.71	-83,911	7,470	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-808	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-41,602	1,818	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	210	-49,100	7,321	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	210	-5,502	825	-%
Feb 13, 2024	MORGAN STANLEY	sold off	-100	-13,518	-	-%

Are Funds Buying or Selling KTRA?

Are funds buying KTRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KTRA

No. of Funds

Unveiling Kintara Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	lind global fund ii lp	0.1%	75,472	SC 13G/A
Apr 20, 2022	lind global fund ii lp	5.8%	3,773,586	SC 13G
Feb 07, 2022	pilkiewicz carolyn	2.41%	1,170,290	SC 13G/A
Feb 08, 2021	pilkiewicz carolyn	7.03%	1,732,789	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	3.5%	900,125	SC 13G/A
Nov 16, 2020	pilkiewicz carolyn	9.15%	2	SC 13G

Recent SEC filings of Kintara Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	425	Prospectus Filed
Apr 03, 2024	8-K	Current Report
Apr 03, 2024	425	Prospectus Filed
Mar 13, 2024	RW	RW
Feb 27, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 22, 2024	8-K	Current Report
Feb 14, 2024	8-K	Current Report
Feb 14, 2024	10-Q	Quarterly Report

Peers (Alternatives to Kintara Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Kintara Therapeutics, Inc. News

Latest updates

Kintara Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2014Q1	2013Q4	2013Q3	2013Q2	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4	2011Q3	2011Q2	2011Q1	2010Q4	2010Q3
Revenue	-100.0%	-	620	691	1,180	3,250	3,780	5,623	6,175	6,726	3,162	250	6,872	13,493	6,410
Costs and Expenses	-	-	-	-	-	-	-	-	-	10,916	3,858	-	-	14,568	7,910
Interest Expenses	198.6%	2,015	-2,044	-2,029	1,992	1,886	1,900	1,876	1,864	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	27.6%	1,885	1,477	3,979	6,740	9,917	13,210	15,948	12,798	17,718	22,343	13,543	18,853	20,489	23,131	2,938	5,102	6,508	8,364	4,037	2,457	4,038
Current Assets	51.5%	1,186	783	3,270	6,016	9,178	8,156	13,258	10,093	14,998	20,108	11,793	16,588	17,717	22,955	2,851	5,099	6,502	8,354	4,025	2,442	4,020
Cash Equivalents	204.6%	658	216	1,535	3,045	4,874	7,085	11,780	8,839	14,064	19,339	10,537	15,718	17,158	22,602	2,392	4,973	6,348	8,060	3,719	2,152	3,703
Net PPE	0.7%	699	694	709	724	739	754	90.00	105	120	135	150	165	172	175	2.00	-	-	-	-	-	-
Liabilities	-41.5%	2,049	3,503	3,248	2,954	3,319	3,592	4,153	3,412	3,616	3,180	2,962	2,735	2,904	2,577	2,675	1,382	1,027	1,339	2,070	1,198	1,268
Current Liabilities	-43.9%	1,870	3,336	3,082	2,790	3,239	3,516	3,990	3,240	3,438	3,001	2,780	2,533	2,727	2,389	2,675	-	-	-	2,070	1,198	1,268
Shareholder's Equity	91.9%	-164	-2,026	731	3,786	6,598	9,618	11,795	9,386	14,102	19,163	10,581	16,118	17,585	20,554	263	3,721	5,481	7,025	1,968	1,259	2,769
Retained Earnings	-0.7%	-155,537	-154,512	-151,375	-148,038	-144,772	-141,316	-136,356	-130,908	-125,550	-119,655	-111,225	-104,489	-97,846	-92,427	-69,721	-65,893	-63,933	-62,188	-60,578	-57,988	-56,299
Additional Paid-In Capital	2.3%	145,090	141,855	141,438	141,156	140,571	138,278	135,575	127,670	126,781	125,074	106,821	100,828	93,551	89,777	65,148	56,395	56,264	56,098	50,955	47,022	46,828
Shares Outstanding	-	-	-	1,620	1,596	1,554	1,464	974	879	828	686	518	585	420	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	12.00	-	-	-	24,700	-	-	-	26,900	-	-	-	7,700	-	-	-	8,400

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-60.7%	-2,117	-1,317	-1,508	-1,827	-2,161	-6,369	-4,992	-5,223	-5,104	-5,073	-4,689	-4,630	-5,431	-4,110	-2,578	-1,373	-1,711	-2,266	-1,812	-1,464	-964
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.00	160	51.00	71.00	100	123
Cashflow From Investing	-	-	-	-	-	-	-232	-	-	-	-	-	-8.00	3.00	969	-	-	-	-	-	-	-
Cashflow From Financing	129050.0%	2,579	-2.00	-2.00	-2.00	-50.00	1,906	7,933	-2.00	-171	13,875	-492	3,198	-16.00	23,351	-3.00	-2.00	-1.00	6,607	3,379	-85.87	783

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KTRA Income Statement

2023-12-31

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Expenses
Research and development	$ 111	$ 2,059	$ 1,970	$ 5,230
General and administrative	908	1,440	2,011	2,915
Operating expenses	(1,019)	(3,499)	(3,981)	(8,145)
Other income (loss)
Foreign exchange	(6)	0	(8)	11
Interest, net	2	45	4	84
Other income (loss)	(4)	45	(4)	95
Net loss for the period	(1,023)	(3,454)	(3,985)	(8,050)
Computation of basic loss per share
Net loss	(1,023)	(3,454)	(3,985)	(8,050)
Series A Preferred cash dividend	(2)	(2)	(4)	(4)
Net loss for the period attributable to common stockholders	$ (1,025)	$ (3,456)	$ (4,162)	$ (8,416)
Basic and fully diluted loss per share	$ (0.24)	$ (2.1)	$ (1.37)	$ (5.42)
Basic and fully diluted weighted average number of shares	4,337,000	1,643,000	3,027,000	1,554,000
Preferred Stock Series C
Computation of basic loss per share
Preferred stock dividend			$ (173)	$ (362)

KTRA Balance Sheet

2023-12-31

Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 658	$ 1,535
Subscriptions receivable	103
Prepaid expenses, taxes and other receivables	311	660
Clinical trial deposit	114	1,075
Total current assets	1,186	3,270
Property and equipment, net	699	709
Total assets	1,885	3,979
Current liabilities
Accounts payable and accrued liabilities	1,722	2,784
Total current liabilities	1,870	3,082
Milestone payment liability	179	166
Total liabilities	2,049	3,248
Stockholders' equity
Common stock Authorized 75,000 shares at December 31, 2023(June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 10,167 issued at December 31, 2023 (June 30, 2023 - 1,692)	10	2
Additional paid-in capital	145,090	141,438
Accumulated deficit	(155,537)	(151,375)
Accumulated other comprehensive income	21	21
Total stockholders' equity	(164)	731
Total liabilities and stockholders' equity	1,885	3,979
Related Party
Current liabilities
Related party payables	148	298
Preferred Stock Series A
Stockholders' equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders' equity
Preferred stock	$ 9,973	$ 10,366

About Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

CEO	Mr. Robert E. Hoffman B.B.A., C.P.A., CPA
WEBSITE	kintara.com
INDUSTRY	Biotechnology
EMPLOYEES	3

Kintara Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Kintara Therapeutics, Inc.? What does KTRA stand for in stocks?

KTRA is the stock ticker symbol of Kintara Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kintara Therapeutics, Inc. (KTRA)?

As of Tue May 07 2024, market cap of Kintara Therapeutics, Inc. is 5.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KTRA stock?

You can check KTRA's fair value in chart for subscribers.

What is the fair value of KTRA stock?

You can check KTRA's fair value in chart for subscribers. The fair value of Kintara Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kintara Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KTRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kintara Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KTRA is over valued or under valued. Whether Kintara Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kintara Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KTRA.

What is Kintara Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, KTRA's PE ratio (Price to Earnings) is -553.26 and Price to Sales (PS) ratio is 1.57 Million. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTRA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Kintara Therapeutics, Inc.'s stock?

In the past 10 years, Kintara Therapeutics, Inc. has provided -0.554 (multiply by 100 for percentage) rate of return.